AA
RPRX

ALPS Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

ALPS Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-12,064
Closed -$104K – 702
2015
Q1 		$104K Buy
+12,064
New +$108K ﹤0.01% 656

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

ALPS Advisors's RPRX Position: Q2 2015 in Review

ALPS Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 12,064 shares — an estimated $104K sold.

ALPS Advisors first reported a position in RPRX in Q1 2015 and held it in 1 quarter. The position peaked at $104K in Q1 2015. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

  • ALPS Advisors reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
  • ALPS Advisors sold 12,064 Repros Therapeutics Inc. shares in Q2 2015, an estimated $104K.
  • ALPS Advisors first reported a position in Repros Therapeutics Inc. in Q1 2015 and held it in 1 quarter.
  • ALPS Advisors's Repros Therapeutics Inc. position peaked at $104K in Q1 2015.
  • 64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on ALPS Advisors's 13F filing for Q2 2015, filed 12 Aug 2015.